The role of vasodilator therapy in heart failure.
This article has attempted to summarize the current status of the therapeutic use of vasodilator drugs in acute and chronic heart failure. It is apparent from the increasing number of publications in this area that this alternative to more standard forms of therapy is likely to find a permanent and important place in the management of patients with heart disease. It should also be apparent that ideal drugs for the therapy of chronic heart failure are not yet available. Nevertheless, it is probable that such drugs will emerge and become at least as important as the routine use of digitalis in such patients.
D000818:Animals; D001022:Aortic Valve Insufficiency / Q000503:physiopathology; D003327:Coronary Disease / Q000503:physiopathology; D006321:Heart / Q000503:physiopathology; D006333:Heart Failure / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D007022:Hypotension / Q000139:chemically induced; D008944:Mitral Valve Insufficiency / Q000503:physiopathology; D009200:Myocardial Contraction; D009203:Myocardial Infarction / Q000150:complications; D009206:Myocardium / Q000378:metabolism; D005996:Nitroglycerin / Q000494:pharmacology; D009599:Nitroprusside / Q000494:pharmacology; D010101:Oxygen Consumption; D010646:Phentolamine / Q000494:pharmacology; D011312:Pressure; D011379:Prognosis; D014294:Trimethaphan / Q000494:pharmacology; D014665:Vasodilator Agents / Q000009:adverse effects / Q000627:therapeutic use*
D014665:Vasodilator Agents; D009599:Nitroprusside; D014294:Trimethaphan; D005996:Nitroglycerin; D010646:Phentolamine